Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from ACACIA-HCM (Assessment Comparing ...
Topline data from the ACACIA-HCM study reveal that the cardiac myosin inhibitor aficamten met all primary and key secondary endpoints, offering a potential new treatment pathway for patients with ...
Marigold flower proteins exhibit solubility, emulsifying, and antioxidant properties with potential applications in food ...
In Nepal’s UNESCO-listed Bhaktapur, multi-generational artists keep thangka alive as both sacred practice and painstaking ...
Most gardeners water on a gut feeling rather than a plan, setting a schedule and sticking to it regardless of what the soil ...
Trial Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance With Consistent Positive Findings Across Key ...
Blum: 2026 has been a remarkable period for Cytokinetics, Incorporated and one that I believe reflects the emerging promise of what we have been building here for over 25 years. Most notably, we ...
Today, we will talk about our first quarter 2026 performance, our main achievements, and our priorities for the future. After the presentation, we will be available for the Q&A session, where our team ...
Barchart on MSN
Why Meta stock is objectively cheap at current levels
The last several days on the markets have been highly eventful, and the reaction of investors to the corporate reporting of ...
Background Secondary tricuspid regurgitation (TR) often develops or persists following left-sided valve surgery. However, its ...
Background Patients with adult congenital heart disease (ACHD) frequently develop late complications despite early surgical ...
To prove the point, Hennessey took it to the Circuit of the Americas F1 circuit and set a new production car lap record, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results